

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,

**Karachi**

No.2/2/2003-F.Sec.

Dated: 03-03-2007

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 2-12-2006 TO BE PUBLISHED ON 05/03/2007 IN  
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1561/2006	<b><u>27-11-2005</u></b> Bayer HealthCare LLC. USA. (Priority 29-11-2005 USA)	“Method of screen printing with semi-continuous replenishment”
1562/2006	Elililly and Company. USA. (Priority 25-10-2001 US) <b>Divisional</b>	“A Pharmaceutically acceptable base addition salt of an N-[benzoyl]-heteroarylsulfonamide compound for use in the treatment of susceptible neoplasms”
1563/2006	Vimar SPA. Italy. (Priority 30-12-2005 Italy)	“Bus modem for building and industrial electrical systems”
1564/2006	Merck & Co. Inc. USA. (Priority 05-12-2005 US)	“P38 Kinase inhibiting agents”
1565/2006	<b><u>28-11-2006</u></b> Novartis AG. Switzerland. (Priority 29-11-2005 US)	“Formulations for quinolinones”
1566/2006	Bayer CropScience AG. Germany. (Priority 03-12-2005 Germany)	“Fungicidal active compound combinations”
1567/2006	Halliburton Energy Services, Inc. USA. (Priority 30-11-2005 USA)	“Compositions and methods for producing guar gum and for using the guar gum in treating a subterranean formation”
1568/2006	N.V. Organon. Netherlands. (Priority 01-12-2005 EP)	“8-Azabicyclo [3.2.1.]octane derivatives”
1569/2006	Otsuka Pharmaceutical Factory, Inc. Japan.	“Method for reinforcing weak sealed portion of multi-chamber medical container”

	(Priority 29-11-2005 Japan)	
1570/2006	Merck & Co. Inc. USA. (Priority 07-12-2005 US)	“Polymorphs of an androgen receptor modulator”
1571/2006	Novartis AG. Switzerland. (Priority 25-06-1998 Swiss) <b>Divisional</b>	“A pharmaceutically acceptable salt of N-substituted 2-amino-1-[2,7-dichloro-9-(ARYL)-9H-fluoren-4-YL)-ethanol, process of its preparation and a pharmaceutical composition comprising thereof”
	<b><u>29-11-2006</u></b>	
1572/2006	Berz pharma GmbH & Co. KGAA. Germany. (Priority 30-11-2005 US)	“Neramexane MR matrix tablet”
1573/2006	ESCO Corporation. USA. (Priority 21-12-2005 US)	“Wear assembly”
1574/2006	UCB S.A. Belgium. (Priority 09-12-2005 US)	“Antibody molecules having specificity for human IL-6”
1575/2006	Glaxo Group Limited. Great Britain. (Priority 08-02-2002 GB) <b>Divisional</b>	“A pharmaceutically acceptable salt of a diazabicyclic compound, process for its preparation and a pharmaceutical composition comprising it”
1576/2006	Jean-Pierre Couzinier. France. (Priority 01-12-2005 France)	“Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof”
1577/2006	AstraZerneca AB. Sweden. (Priority 30-11-2005 USA)	“New combination dosage form”
	<b><u>30-11-2006</u></b>	
1578/2006	Zpey System AS. Norway. (Priority 01-12-2005 Norway)	“Fishing rod”
1579/2006	Pfizer Limited.	“Spirocyclic derivatives”

	United Kingdom. (Priority 02-12-05 USA)	
1580/2006	Arch Chemicals, Inc. USA. (Priority 01-12-2005 US)	“Coated calcium hypochlorite composition “
1581/2006	1. AstraZeneca AB. Sweden. 2. NPS Pharmaceuticals, Inc. USA. (Priority 15-12-2005 US)	“Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators”
1582/2006	Aventis Pharma S.A. France. (Priority 05-09-2002 France) <b>Divisional</b>	“A racemate, enantiomer, diastereoisomer or a mixture thereof, or a tautomer or a pharmaceutically acceptable salt of an aminoindazole compound and a pharmaceutical composition including it”
1583/2006	Boehringer Ingelheim International GmbH. Germany. (Priority 02-12-2005 EP)	“Dispensing device”
1584/2006	Boehringer Ingelheim International GmbH. Germany. (Priority 02-12-2005 EP)	“Dispensing device, storage device and method for dispensing a formulation”
1585/2006	Boehringer Ingelheim International GmbH. Germany.  (Priority 01-12-2005 Germany)	“Inhalers and reservoir for a powder medicinal formulation, related processes and uses”
	<b><u>01-12-2006</u></b>	
1586/2006	Bayer Pharmaceuticals Corporation. USA. (Priority 02-12-2005 USA)	“Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis”
1587/2006	Merck Patent GmbH. Germany. (Priority 05-12-2005 DE)	“Pyridazinone derivatives”

1588/2006	Unilever PLC. England. (Priority 06-12-2005 PCT)	“Plant extracts and compositions for reducing blood lipid levels”
1589/2006	Bayer CorpScience GmbH. Germany. (Priority 05-02-2003 EP) <b>Divisional</b>	“Amino-1,3,5-triazine N-substituted with chiral bicyclic radical process for preparation and method for using them”
	<b><u>02-12-2006</u></b>	
1590/2006	The Mount Sinai Medical Center of New York University. USA. (Priority 02-12-2005 USA)	“Chimeric viruses presenting non-native surface proteins and uses thereof”
1591/2006	Basf Aktiengesellschaft. Germany. (Priority 22-12-2005 US)	“Pesticidal Compounds”
1592/2006	Bayer HealthCare AG. Germany. (Priority 21-12-2005 Germany)	“Novel acyclically substituted fuopyrimidine derivatives and use thereof”
1593/2006	Theravance Inc. USA. (Priority 14-02-2003 USA) <b>Divisional</b>	“A biphenyl compound, method of preparation and pharmaceutical compositions thereof for use in treating pulmonary disorders”

### **SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139190	Invista Technologies S.a.r.l., USA	862/2004
139191	Methanol Casale S.A., Switzerland	863/2004
139192	Vaqar ul Hassan, Muhammad Tariq, PCSIR, Peshawar, Pakistan	874/2004

139193	Mehmood Ullah Mustafai, Karachi, Pakistan	877/2004
139194	Casale Chemicals S.A., Switzerland	880/2004
139195	Merz Pharma GmbH & Co. KGAA, Germany	882/2004
139196	Reckitt Benckiser (Australia) Pty. Limited, Australia	884/2004
139197	Reckitt Benckiser (Australia) Pty. Limited, Australia	885/2004
139198	Wyeth, USA	894/2004
139199	Reckitt Benckiser (Australia) Pty. Limited, Australia	608/2006

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Tel: 9215488